articleThe Lancet OncologyMay 24, 2017Closed access

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

University of California, Los Angeles · Weill Cornell Medicine · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,086
total citations
FWCI
51.26
Percentile
100%
References
32
Citations per year

Authors

8

Topics & keywords

Keywords
  • Medicine
  • Pembrolizumab
  • Common Terminology Criteria for Adverse Events
  • Pneumonitis
  • Internal medicine
  • Lung cancer
  • Radiation therapy
  • Discontinuation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.